Nuevos datos presentados en el 64º Congreso Anual AAN destacan el compromiso … – elEconomista.es
Nuevos datos presentados en el 64º Congreso Anual AAN destacan el compromiso ... elEconomista.es ... de investigación de su cartera en última fase, incluido: BG-12, interferón beta-1a PEGylado, y el proceso de alto rendimiento de daclizumab (DAC HYP) para EM; y dexpramipexole, un tratamiento potencial para esclerosis lateral amiotrófica (ELA). |
Haga doble click sobre una palabra para ver su signifcado – elEconomista.es
Haga doble click sobre una palabra para ver su signifcado elEconomista.es ... de investigación de su cartera en última fase, incluido: BG-12, interferón beta-1a PEGylado, y el proceso de alto rendimiento de daclizumab (DAC HYP) para EM; y dexpramipexole, un tratamiento potencial para esclerosis lateral amiotrófica (ELA). |
Biogen Idec to present new neurology data at AAN 2012 meeting – Zenopa
Biogen Idec to present new neurology data at AAN 2012 meeting Zenopa New data will highlight the safety and efficacy of the marketed products Tysabri, Avonex and Fampyra, as well as results from investigational trials of key late-stage compounds such as BG-12, PEGylated interferon beta-1a and daclizumab high-yield ... BIOGEN IDEC INC. : New Data Presented at 64th AAN Annual Meeting Highlights ... |
Partager BFM sur – BFM Business
Partager BFM sur BFM Business ... de son pipeline de molécules en phase finale, dont : BG-12, interféron bêta-1a pégylé et DAC HYP (procédé à haut rendement du daclizumab) pour la SEP ; et dexpramipexole, un traitement potentiel pour la sclérose latérale amyotrophique (SLA). |
Biogen Idec presenteert nieuwe data op American Academy of Neurology … – Nieuws.nl
Biogen Idec presenteert nieuwe data op American Academy of Neurology ... Nieuws.nl Daarnaast presenteert Biogen Idec de resultaten van onderzoeksproeven zoals de BG-12, PEGylated interferon beta-1a, en daclizumab high-yield process (DAC HYP) voor multiple sclerosis (MS); en dexpramipexole, een potentiële behandeling van amyotrophic ... |
Biogen Idec assume un ruolo significativo durante l’importante congresso di … – ANSA.it
Biogen Idec assume un ruolo significativo durante l'importante congresso di ... ANSA.it ... sua pipeline per terapie nelle fasi finali, fra cui: BG-12, interferone pegilato beta-1a e il processo daclizumab ad alto rendimento (DAC HYP) per la SM; oltre al dexpramipexole, un potenziale trattamento per la sclerosi laterale amiotrofica (ALS). |
Auf der 64. AAN-Jahrestagung präsentierte Daten unterstreichen das Engagement … – Live-PR.com (Pressemitteilung)
Auf der 64. AAN-Jahrestagung präsentierte Daten unterstreichen das Engagement ... Live-PR.com (Pressemitteilung) ... PEGyliertes Interferon Beta-1a und Daclizumab High-Yield Process (DAC HYP) für MS sowie Dexpramipexol, eine potenzielle Therapie für amyotrophe Lateralsklerose (ALS). "Wir sind fest entschlossen, neue wissenschaftliche Erkenntnisse zu nutzen, ... |
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s … – EON: Enhanced Online News (press release)
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's ... EON: Enhanced Online News (press release) ... and FAMPYRA ® (prolonged-release fampridine tablets) – the company will present results from investigational trials of its late-stage pipeline, including: BG-12, PEGylated interferon beta-1a, and daclizumab high-yield process (DAC HYP) for MS; ... |
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s … – Financial Post
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's ... Financial Post ... and FAMPYRA ® (prolonged-release fampridine tablets) – the company will present results from investigational trials of its late-stage pipeline, including: BG-12, PEGylated interferon beta-1a, and daclizumab high-yield process (DAC HYP) for MS; ... |
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s … – MarketWatch (press release)
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's ... MarketWatch (press release) ... and FAMPYRA(R) (prolonged-release fampridine tablets) -- the company will present results from investigational trials of its late-stage pipeline, including: BG-12, PEGylated interferon beta-1a, and daclizumab high-yield process (DAC HYP) for MS; ... |